secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-085646
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics receives Nasdaq delisting notice; shares to suspend Mar 5, 2026
--------------------------------------------------------------------------------

- Received delisting determination letter on Feb 24, 2026 for failing minimum bid price of $1.00 per share.
- Trading suspension on Nasdaq effective March 5, 2026 unless hearing requested before Nasdaq Hearings Panel.
- Company evaluating appeal and strategic alternatives including possible wind-down or bankruptcy.
- Also noncompliant with $35M minimum market value of listed securities and other listing standards.
- Warns shareholders are unlikely to receive any meaningful distribution in a potential dissolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000119312526085646/0001193125-26-085646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000119312526085646/itrm-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-085646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer